Amaero (ASX:3DA) finishes A$72m capex on time, eyes a US listing

Third atomiser is live, titanium restarts in July, and the next raise targets a Nasdaq audience

Amaero (ASX:3DA) has done something unusual for a small-cap industrial story. It has finished a three-year, A$72 million capital investment plan on schedule and on budget, and confirmed the third EIGA Premium atomiser at its Tennessee facility is now commissioned ahead of schedule.

The headline numbers are worth pausing on. Amaero now has roughly 200 tonnes of annual refractory alloy powder capacity and around 480 tonnes of titanium alloy capacity, making it the largest US domestic producer of spherical refractory and titanium powders. That is the scale the company has been promising defence customers for two years, and it is now physically in the building.

Behind the scenes, two other things shifted today. Re-domiciliation to the United States is complete ahead of schedule, and management is openly flagging a potential US initial public offering in late CY2026 or early CY2027. So the capex story is closing, and the capital markets story is opening.

The one caveat is the May safety incident. Titanium production has been paused, a full review with Jensen Hughes is underway, and management expects to restart in July with a safety-first posture.

The capex chapter just closed, on time and on budget

Finishing a A$72 million build on budget is rare in industrial micro-caps. The first atomiser came online in June 2024, the second in June 2025, and the third is now live a few weeks ahead of plan. The fourth remains on track for June 2027.

For investors who have watched the share register dilute through the build phase, this matters. The argument for owning Amaero has always been that once the atomisers are running, the unit economics improve sharply because argon and fixed costs spread across more tonnes. With three atomisers commissioned, that thesis stops being a forecast and starts being a number you can audit each quarter.

The argon recycling plant is still tracking to first-quarter CY2027 commissioning. That single piece of kit is what shifts the cost curve, because argon consumption is one of the largest variable inputs in the EIGA process.

The titanium pause is the live risk, not the capex

Titanium is the higher-volume side of the powder business and was the engine behind the 301% Q3 revenue growth we wrote about earlier this year. Pausing it to run a full safety review is the right call, but it does put a question mark over near-term revenue cadence.

Our concern is straightforward. Investors were already modelling a step-up in the June quarter, and a July restart means the FY26 exit run-rate will likely sit below where consensus had it before the May incident. Management has been clear that customers depend on reliable supply, so a clean restart matters more than squeezing an extra week of production.

The skeptical read is that any further slippage past July would dent credibility just as the company prepares to court US institutional investors. That is a tight window with very little margin for error.

The US listing is the real strategic pivot

Re-domiciliation is done, the PCAOB audit with BDO USA is progressing, and management has put a window on a potential US IPO of late CY2026 or early CY2027. That is a meaningful change in the investor base Amaero is targeting.

We think this is the most important sentence in today’s announcement, even though it sits below the capex headline. A US listing puts Amaero in front of defence-focused institutional investors who understand the rearmament thesis, value sovereign supply chain assets, and pay materially higher multiples for them than the ASX small-cap market has been willing to.

It also explains why management pushed so hard to finish the capex plan on schedule. Walking into a Nasdaq roadshow with three atomisers running, a clean audit, and a defined PM-HIP growth path is a very different conversation from doing it mid-build.

The Investors Takeaway for Amaero

The next ninety days will tell investors more about Amaero than the last twelve months did. A safe titanium restart in July, followed by a Q1 FY27 print that shows the third atomiser contributing meaningful volume, is what underwrites the US listing story. Miss either of those, and the IPO window narrows.

On the upside, the company now has the largest US domestic capacity for refractory and titanium powders, a finished capex plan, and a defence customer base actively pulling for more supply. That is a credible package to put in front of US institutional investors who understand why sovereign manufacturing is being repriced.

Investors can read our previous coverage of this name at stocksdownunder, where we covered the 301% Q3 revenue growth and the runway maths that set up today’s announcement.